All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Join our
How to sequence BCMA-directed therapies in early relapsed/ refractory multiple myeloma
At the ESH 7th Translational Research Conference:
Multiple Myeloma
with Martin Kaiser, Mohamad Mohty, and Rakesh Popat
Saturday, October 5, 2024 | 09:10-10:10 CEST
Register nowThis independent educational activity is funded by GSK. All content is developed independently by the faculty. The funders are allowed no influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma hub is an independent medical education platform, sponsored by Sanofi, Bristol Myers Squibb, GSK and Roche, and supported through a grant from Janssen Biotech, Inc. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Rahul Banerjee, Fred Hutchinson Cancer Research Center, Seattle, US. We asked, What is the impact of dexamethasone dose strength on outcomes in newly diagnosed multiple myeloma?
What is the impact of dexamethasone dose strength on outcomes in NDMM?
Banerjee discusses the toxicity profile of dexamethasone in patients with newly diagnosed multiple myeloma treated with a standard dose of ~40 mg weekly. He then explores the impact of reducing dexamethasone dose strength on incidence and patient outcomes, highlighting both the frequency of adverse events and differences in efficacy outcomes. He concludes by explaining the implications of this data on future dexamethasone use and how to determine the optimal initial dose strength.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox